Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (393)
NICE advice (1)
Quality standard (7)
Guidance programme
Guidance programme
Clinical guidelines (26)
Diagnostics guidance (7)
Health technology evaluations (13)
Highly specialised technologies guidance (6)
Interventional procedures guidance (15)
Medical technologies guidance (9)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (318)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 176 to 200 of 401
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Intrapartum Care - Water birth: second stage of labour
NICE guideline
14 November 2025
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]
Technology appraisal guidance
28 October 2026
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Technology appraisal guidance
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Technology appraisal guidance
TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]
Technology appraisal guidance
TBC
Iptacopan for treating complement 3 glomerulopathy [ID6283]
Technology appraisal guidance
28 January 2026
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]
Technology appraisal guidance
11 February 2026
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]
Technology appraisal guidance
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Technology appraisal guidance
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Technology appraisal guidance
TBC
Kidney Cancer
NICE guideline
19 March 2026
Kidney Cancer Quality Standard
Quality standard
TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
Technology appraisal guidance
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]
Technology appraisal guidance
TBC
Leadless cardiac pacemaker implantation for bradyarrhythmias
Interventional procedures guidance
25 February 2026
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]
Technology appraisal guidance
TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
Technology appraisal guidance
11 March 2026
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Technology appraisal guidance
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Technology appraisal guidance
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Technology appraisal guidance
TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Technology appraisal guidance
TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Technology appraisal guidance
TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Technology appraisal guidance
TBC
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor [ID6434]
Technology appraisal guidance
TBC
Low energy contact X-ray brachytherapy for rectal cancer
Interventional procedures guidance
13 November 2025
Previous page
1
…
6
7
Current page
8
9
10
…
17
Page
8
of
17
Next page
Results per page
10
25
50
All
Back to top